(Reuters) - Roche will pay Alnylam $331 million upfront in cash and equity investment, including a stake of 1.975 million Alnylam shares at $21.50 each, or just under 5 percent of Alnylam's outstanding common stock, the two firms said on Monday.
For that investment, Roche gets a non-exclusive license to Alnylam's technology platform. The alliance will initially focus on oncology, respiratory diseases, metabolic diseases and certain liver diseases.
Read more at Reuters.com Business News
For that investment, Roche gets a non-exclusive license to Alnylam's technology platform. The alliance will initially focus on oncology, respiratory diseases, metabolic diseases and certain liver diseases.
Read more at Reuters.com Business News
No comments:
Post a Comment